Jun. 24, 2011 (Baystreet.ca) --
Microbix
Biosystems Inc. (TSX-V: MBX) is a biotechnology company leveraging
its long-standing core virology business to develop products targeted to large
global market opportunities.
The
Company’s potentially more-lucrative
large-market pipeline of products include: Kinlytic (Urokinase), VIRUSMAX™
(Virus Yield Enhancement Technology), and LumiSort™ (livestock sex selection
technology). In addition, the Company
has established a JV in Hunan, China for the manufacture and distribution of
influenza vaccines using VIRUSMAX™ technology.
Microbix
has received a notice from the U.S. Patent and Trademark Office, allowing all
claims of its first pending U.S. patent application for LumiSort™ sperm-sexing
technology for the livestock industries. The Company will exercise its option
to request the issuance of the LumiSort™ patent once it takes additional
strategic steps to strengthen its position.
To read
the complete Perspective, click here: http://www.eresearch.ca/_report/MBX_062311-B.pdf
eResearch is preparing a
comprehensive research report on Microbix Biosystems Inc. This report will
contain a Recommendation, a 12-month Target Price, and analyst views and
opinions.
About Us: eResearch is a primary source for professional investment research,
focused primarily on small- and mid-cap companies. Our research and analysis is
of institutional quality, and has the potential for reaching millions of global
investors through our extensive electronic distribution network.
eResearch posts all its reports and
articles on its website, www.eresearch.ca,
and subscription is FREE.
Contact:
eResearch: Bob Weir, CFA, Managing Director,
Research Services
Telephone:
(416) 703-6258 Ext 221; E-mail: bweir@eresearch.ca